Apogee Therapeutics (APGE) News Today

ProShare Advisors LLC purchased a new stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 10,038 shares of the company's stock, valued at approximatel

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) has received a consensus recommendation of "Buy" from the eight analysts that are currently covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 12-month price objec

Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up to $45.93

Apogee Therapeutics (NASDAQ:APGE) Shares Up 4%

Apogee Therapeutics (NASDAQ:APGE) Sees Large Volume Increase

Jennison Associates LLC increased its position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 192.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 302,892 shares of the company's stock after purchasing an additional 199,14

Capstone Investment Advisors LLC purchased a new stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 41,001 shares of the company's stock, valued at approxi

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 5,995 shares of the firm's stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total transaction of $225,412.00. Following the sale, the insider now directly owns 294,793 shares of the company's stock, valued at approximately $11,084,216.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Apogee Therapeutics (NASDAQ:APGE) Trading Down 2.7%

Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight brokerages that are covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 1-year t

Apogee Therapeutics (NASDAQ:APGE) Trading 5.3% Higher

Apogee Therapeutics (NASDAQ:APGE) Shares Down 3.6%

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) saw a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 6,500,000 shares, a growth of 36.0% from the May 15th total of 4,780,000 shares. Currently, 17.6% of the shares of the stock are short sold. Based on an average daily volume of 576,600 shares, the days-to-cover ratio is currently 11.3 days.

Blackstone Inc. raised its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 17.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 351,810 shares of the company's stock after buying an additional 52,688 shares duri

Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up to $43.21

Braidwell LP grew its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 38.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 681,101 shares of the company's stock after buying an addition

TD Asset Management Inc grew its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 217.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 100,846 shares of the company's stock after purchasing an additional 69,052

Affinity Asset Advisors LLC decreased its position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 48.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 537,093 shares of the company's stock aft

Swiss National Bank bought a new stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 33,000 shares of the company's stock, valued at a

Franklin Resources Inc. boosted its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 9.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,089,780 shares of the company's stock after buying an additional 92,423 shares duri

Jump Financial LLC purchased a new position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,344 shares of the company's stock, valued at a

Apogee Therapeutics (NASDAQ:APGE) Trading Down 4%

Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) - Analysts at Wedbush upped their Q2 2024 earnings per share estimates for shares of Apogee Therapeutics in a research note issued to investors on Monday, May 13th. Wedbush analyst D. Nierengarten now anticipates that the company will post ear

Apogee Therapeutics (NASDAQ:APGE) Sees Strong Trading Volume

Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) - Equities researchers at Wedbush issued their Q1 2025 EPS estimates for Apogee Therapeutics in a research note issued to investors on Monday, May 13th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.63)

Wedbush reaffirmed an "outperform" rating and issued a $87.00 price target on shares of Apogee Therapeutics in a research report on Monday.

Bank of America began coverage on Apogee Therapeutics in a research note on Friday. They issued a "buy" rating and a $80.00 price target for the company.

Jennison Associates LLC acquired a new stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 103,744 shares of the company's stock,

Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 6.2%

Apogee Therapeutics (NASDAQ:APGE) Shares Down 6.1%

Apogee Therapeutics (NASDAQ:APGE) Shares Up 3.3%

Vanguard Group Inc. acquired a new stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,121,764 shares of the compan

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 4,600,000 shares, a growth of 50.8% from the March 15th total of 3,050,000 shares. Approximately 13.1% of the shares of the company are sold short. Based on an average trading volume of 680,700 shares, the days-to-cover ratio is currently 6.8 days.